Odonate's Oral Taxane Tesetaxel Shows PFS Benefit In Metastatic Breast Cancer Phase III

 
• By Jessica Merrill

The convenient oral therapy could have benefits over more traditional infused taxane chemotherapies, and a new drug application filing is planned for 2021.

Stepping stones
Odonate hopes tesetaxel is on the path to FDA approval • Source: Shutterstock

More from Clinical Trials

More from R&D